Eur J Cancer: Results of Phase 3 clinical trials of critical prostate cancer in the combined radiotherapy of androgen deprivation therapy

The role of androgen deprivation therapy (ADT) combined radiotherapy (RT) in mid-risk prostate cancer (IRPC) remains controversial, especially in patients receiving incremental dose radiotherapy (DRT).
in this study, Nabid et al. compared the prognosis of IRPC patients treated with ADT and two different doses of RT with those treated simply with RT.
December 2000-September 2010, 600 IRPC patients were randomly divided into three groups: ADT-RT 70 Gy (ADT-DERT70), ADT-76 Gy (DERT76) and PURE 76 Gy (DERT76) group, ADT 76 Gy (DERT76) group, ADT treatment for 6 months.
end of the disease is bio-chemical failure (BF), and the secondary endpoint is total lifetime (OS) and toxicity.
the median follow-up rate of 11.3 years (quarter-digit range: 10.9-11.7 years), compared with the ADT-RT70 group and ADT-DERT76 group, the BF rate of patients treated with DERT 76 alone (32%, 18% and 14%, respectively), p.lt;0.001), and The rate of progression of adenocarcinoma (12%, 4.5% and 3.3%, respectively, p-0.001) and prostate cancer mortality (6.5%, 3.0% and 1.5%, p-lt;0.05) were higher, but there was no significant difference between the ADT-RRT70 and ADT-DE76 groups.
no statistical differences in OS in all three groups of patients.
compared to low-dose radiotherapy (70 Gy), high-dose radiotherapy (76 Gy) increased the rate of late gastrointestinal (GI) toxicity at level II and above (16% vs. 5.3%, P.lt;0.001), but there was no significant difference in the effects on the toxicity of the late genitourinary system.
, in patients with IRPC, the addition of six months of ADT on top of RT70 or DERT76 significantly improves BF compared to SINGLE DERT76, while also reducing the risk of prostate cancer death without affecting total survival.
, patients with critical prostate cancer in the ADT joint RT 70GY treatment had effective disease control and lower gastrointestinal toxicity.
。